UK markets closed

Kiromic BioPharma, Inc. (KRBP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.1000-0.0100 (-0.32%)
As of 12:05PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 4.01M
Enterprise value 13.91M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.55
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.13

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-31.04%
S&P500 52-week change 326.49%
52-week high 35.4900
52-week low 30.1600
50-day moving average 32.6026
200-day moving average 31.5375

Share statistics

Avg vol (3-month) 33.98k
Avg vol (10-day) 32.31k
Shares outstanding 51.29M
Implied shares outstanding 61.29M
Float 8963.16k
% held by insiders 118.90%
% held by institutions 10.00%
Shares short (31 Aug 2023) 445.74k
Short ratio (31 Aug 2023) 41.45
Short % of float (31 Aug 2023) 46.82%
Short % of shares outstanding (31 Aug 2023) 43.89%
Shares short (prior month 31 Jul 2023) 462.44k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 313 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-98.48%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -18.05M
Net income avi to common (ttm)-24.35M
Diluted EPS (ttm)-7.4200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.68M
Total cash per share (mrq)2.82
Total debt (mrq)13.58M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.29
Book value per share (mrq)-5.53

Cash flow statement

Operating cash flow (ttm)-22.8M
Levered free cash flow (ttm)-15.57M